Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Phase 2 Terminated 30 enrolled Shuttle Pharmaceuticals, Inc.

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open-label, phase 2 study evaluating the safety and efficacy of oral ropidoxuridine as a radiation-sensitizing agent in patients with newly diagnosed wild-type isocitrate dehydrogenase glioblastoma with an unmethylated O6-methylguanine-DNA methyltransferase promoter, undergoing standard 60 Gy radiotherapy.

Timeline

Start: 2024-09-02
Primary completion: 2025-12-01
Completion: 2025-12-01

Outcome

Outcome not reported

Stopped: “Terminated due to the sponsor's decision.”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ropidoxuridine	Small molecule	960 mg	Oral
Subject	Ropidoxuridine	Small molecule	1200 mg	Oral

Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter

Summary

Timeline

Outcome

Drugs

Indications